Addressing Moral Distress and Burnout in Oncology
Lara Traeger, PhD, discusses recommendations from the American Society of Clinical Oncology for coping with moral distress and burnout.
Lara Traeger, PhD, a licensed clinical psychologist at the Massachusetts General Hospital Cancer Center and an assistant professor in the Department of Psychiatry at Harvard Medical School, discusses recommendations from the American Society of Clinical Oncology (ASCO) for coping with moral distress and burnout.
ASCO recently held a roundtable on this topic of burnout and moral distress, says Trager. The findings from the roundtable were published and showed that things can be improved if the topic was more integrated into the infrastructure of every practice. ASCO also suggests establishing metrics for success in practices to boost morale.
Trager shares recommendations based on her own expertise as well, in relation to promoting and supporting best practices for clinician well-being by highlighting and awarding their efforts.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
